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A B S T R A C T
Antiepileptic drugs-induced Stevens–Johnson syndrome (SJS) is a life-threatening severe cutaneous
adverse reaction. Recent studies in Thailand and Taiwan showed a signiﬁcant association between
phenytoin (PHT)-induced SJS and human leucocyte antigen HLA-B*1502 allele. Although the US FDA had
issued an alert to clinicians, insufﬁcient information is available to recommend testing for HLA-B*1502 in
Asian patients in line for PHT treatment. Therefore, extended studies are necessary to further evaluate
the potential association between PHT-induced SJS and HLA-B*1502 allele in various populations. To
date, no similar data exist in mainland China. Here, we describe two Chinese Han cases of PHT-induced
SJS with negative HLA-B*1502 allele, in which HLA high-resolution genotyping showed two
heterozygous HLA-B*4601/B*5102 and HLA-B*3701/B*4601 allele, respectively. Our ﬁndings provide
evidence to support that other genetic markers or nongenetic factors could contribute to the
susceptibility of PHT-induced SJS, except for HLA-B*1502 allele. Further studies are encouraged to
investigate the genetic link with PHT-induced serious skin reactions in future.
 2011 British Epilepsy Association. Published by Elsevier Ltd. All rights reserved.
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Carbamazepine (CBZ) and phenytoin (PHT) are among the most
common causes of antiepileptic drugs (AEDs)-induced cutaneous
adverse reactions.1 Recent studies have uncovered a strong genetic
association between CBZ-induced Stevens–Johnson syndrome/
toxic epidermal necrolysis (SJS/TEN) and human leucocyte antigen
HLA-B*1502 allele in Asians.2–7 In order to safer AEDs use, the US
FDA and similar control agencies in Canada and Taiwan have
updated the CBZ label to include genetic information, and
recommended screening for HLA-B*1502 allele before starting
CBZ treatment in Asians.8 These signiﬁcant advances in pharma-
cogenetic study inspired much scientiﬁc interest among research-
ers to detect other aromatic antiepileptic drugs, such as PHT and
oxcarbazepine (OXC). Recently, a signiﬁcant association of PHT-
induced SJS/TEN with HLA-B*1502 allele had been observed in
Thailand and Taiwan populations.5,6 However, no pertinent data
exist in mainland China until recently. In the present study, we
report two Chinese Han cases of PHT-induced SJSwho test negative
for HLA-B*1502 allele and review the related literature.* Corresponding author. Tel.: +86 28 85423038; fax: +86 28 85423550.
E-mail address: zhoudong66@yahoo.de (D. Zhou).
1059-1311/$ – see front matter  2011 British Epilepsy Association. Published by Else
doi:10.1016/j.seizure.2011.01.0052. Case report
2.1. Case 1
A 38-year-old Chinese womanwas presented to our emergency
department due to widespread skin rashes and high fever. The
patient had a 5-year history of idiopathic generalized epilepsy.
Sodium valproate (VPA) and CBZ (600 mg daily, respectively) were
prescribed since 2004. The number of epileptic seizures was
signiﬁcantly reduced to about one in every one to two months.
Since July 5, 2009 CBZ was withdrawn due to incomplete seizure
control, and PHT (150 mg/day) was introduced into her therapy to
replace CBZ. Unfortunately, moderate fever and maculopapular
rashes occurred all over the cheeks and arms of the patient since
September 13, 2009. Starting from September 15, 2009, her
temperature reached 39.6 8C, and blisters appeared on her face.
The patient was then admitted to the Department of Dermatology.
On admission, physical examination showed widespread
erythematous macules and papules with blisters and detached
epidermis on her face, neck, trunk, feet, and upper limbs. The
estimated skin detachment was approximately 5% of body surface
area. Scattered skin rashes on the lower limbs and diffuse oral
ulcers were also observed. Laboratory examinations including
routine blood chemistry, abdominal ultrasound scan, thyroid
function, and immunological inspection were not signiﬁcant
abnormal. The patient was diagnosed as PHT-induced SJS. Aftervier Ltd. All rights reserved.
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performed by polymerase chain reaction sequencing-based typing
(PCR-SBT) method. HLA high-resolution genotyping showed a
heterozygous HLA-B*4601/B*5102 allele. After being treated with
steroids and antihistamine for 13 days, the patient greatly
improved and she was discharged.
2.2. Case 2
A 63-year-old Chinese man, with a history of hypertension and
cerebral vascular accidents, was admitted to our hospital with
complaints of low-grade fever and erythema. The patient had not
been diagnosed with hypertension until the occurrence of
intracerebral hemorrhage due to the absence of routine physical
examination. Secondary epilepsy occurred six months after the
surgical treatment of the left intracerebral hemorrhage. PHT
(100 mg/day) was administered since the ﬁrst seizure. Unfortu-
nately, extensive skin rashes and low-grade fever appeared on the
15th day after the antiepileptic therapy. This was followed by the
manifestation of blisters and oral ulcers. Physical examination
showed widespread erythematous macules with blisters and
target-like lesions on his cheeks, trunk, and proximal limbs. The
skin detachment was approximately 2% of body surface area.
Numerous oral ulcers were also observed. The remainder of his
physical examination was normal. Laboratory examinations found
no evidence of internal organ involvement. Clinical history and
laboratory tests excluded other potential causative drugs or
concomitant infections, including over-the-counter drugs, NSAID,
antibiotics and HIV. The patient was diagnosed as PHT-induced SJS
by two dermatologist. HLA genotyping showed a heterozygous
HLA-B*3701/B*4601 allele.
3. Discussion
SJS and TEN are characterized by rapidly expanding blistering
exanthema of purpuric macules and target-like lesions accompa-
nied by mucosal involvement and skin detachment,9 with a
mortality rate that can reach up to 40%.10 The diagnostic criteria of
SJS/TEN are based on the clinical morphology. SJS is deﬁned as skin
detachment of less than 10% of body surface area, an overlap of SJS/
TEN is deﬁned as skin detachment of 10–30% and TEN is deﬁned as
skin detachment of greater than 30%.9 In this study, the two
patients met the diagnostic criteria for PHT-induced SJS according
to Roujeau’s classiﬁcation.9 The ﬁrst case was on two antiepileptic
drugs (PHT and VPA), in which VPA was continuously adminis-
trated formore than four years and no adverse drug reactions were
observed. Other potential causative drugs or infections, including
NSAID, antibiotics and HIV, have also been excluded. Therefore,
PHT was identiﬁed as the culprit agent, although it is unusual that
SJS occurred after taking the medication for over 2 months. It is
worth noting that, when combined treatment with VPA, plasma
concentration of PHT may have a larger change owing to
competitive binding with the protein between drugs. The
interactions between drugs may be partly responsible for the
delayed development of SJS, but this need to be further conﬁrmed
in future.
Owing to the similar structure between PHT and CBZ, the US
FDA is investigating the genetic linkwith PHT-induced serious skinreactions, including SJS and TEN. While insufﬁcient information is
available to recommend testing for HLA-B*1502 in Asian patients
in line for PHT treatment, physicians are still advised to avoid PHT
and fosphenytoin as alternatives to CBZ therapy in patients who
test positive for the HLA-B*1502 allele.11 Previous studies in Hong
Kong and Thailand observed a 100% positive for HLA-B*1502 allele
among patients with PHT-induced SJS.4,5 Recent study in Taiwan
also showed a signiﬁcant association between PHT-induced SJS/
TEN and HLA-B*1502 allele.6 In the present study, HLA high-
resolution genotyping did not detect the presence of HLA-B*1502
allele in both patients, in addition to a commonHLA-B*4601which
has been conﬁrmed as a frequent allele in Han population in
Southwest China.12 Our results indicate that HLA-B*1502 allele is
not a universal marker for PHT-induced SJS, and other genetic
markers or environmental factors may contribute to the genetic
susceptibility of PHT-induced severe cutaneous reactions in Han
Chinese. However, the failure to detect a positive HLA-B*1502
allele in patients with PHT-induced SJS should not be considered as
strong evidence against the FDA’s guideline due to the small
sample size. Caution should be exercised for PHT no matter
whether the patients carry HLA-B*1502 allele. In future, larger
study should be necessary to further evaluate the potential
association between PHT-induced severe cutaneous reactions and
the HLA-B*1502 allele in various populations.
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